主页 > 医药生命 >
【medical-news】单抗在胰腺癌诊断中应用的发展
Early detection and treatment of pancreatic cancer is critical; the best available treatment for pancreatic cancer is surgery, which is only effective at early stages of the disease. But less than 15 percent of patients are diagnosed with pancreatic cancer at an early stage.
Investigators developed the Oregon Pancreas Tumor Registry, which serves two functions: first, it is intended to keep patients at high risk for pancreatic cancer under surveillance, with the goal of early diagnosis. Also, it acts as a biospecimen repository in which patients and families may provide blood, pancreatic ductal fluid and tissue samples. Doctors may then use the samples for pancreatic cancer research, according to Brett C. Sheppard, MD,Professor and Vice-Chairman of Surgery at the Digestive Health Center at the Oregon Health Sciences University (OHSU).
For this study, OHSU researchers in the Oregon Stem Cell Center and in the Department of General Surgery generated and characterized antibodies. These antibodies were developed following the injection of normal pancreas cells into mice. They next took the spleen cells of the mice and fused them with a myeloma cell line, which yields cells that can be grown for long periods of time in the laboratory. These cells secreted antibodies which researchers were then able to screen for reaction with normal pancreatic and pancreatic cancer tissues.
"The antibodies described in this abstract, recognize normal pancreas cells, specifically a population of ductal cells, but recognize many more cells in pancreatic cancer tissue. In addition to recognizing pancreatic cancer, these antibodies recognize gastrointestinal cancers. The next step is to use these antibodies in a sensitive screening assay to determine their full potential in diagnosis of this devastating disease." 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 单抗在胰腺癌诊断中的应用发展
Investigators have developed antibodies that recognize pancreatic cancer. The antibodies were developed through a technique of injecting normal pancreas cells into mice.
研究者们已经研发出了能够识别胰腺癌的抗体。该抗体是通过一项向小鼠体内注射正常胰腺细胞的技术而制得的。
Early detection and treatment of pancreatic cancer is critical; the best available treatment for pancreatic cancer is surgery, which is only effective at early stages of the disease. But less than 15 percent of patients are diagnosed with pancreatic cancer at an early stage.
胰腺癌的早期检测与治疗是非常关键的；对于胰腺癌而言，目前可用的最佳治疗方案是进行外科手术，但手术只能在该疾病的早期有效。目前只有不到15%被诊断为胰腺癌的病人是在早期发现的。
Investigators developed the Oregon Pancreas Tumor Registry, which serves two functions: first, it is intended to keep patients at high risk for pancreatic cancer under surveillance, with the goal of early diagnosis. Also, it acts as a biospecimen repository in which patients and families may provide blood, pancreatic ductal fluid and tissue samples. Doctors may then use the samples for pancreatic cancer research, according to Brett C. Sheppard, MD,Professor and Vice-Chairman of Surgery at the Digestive Health Center at the Oregon Health Sciences University (OHSU).
研究者研发出了俄勒冈胰腺肿瘤登记制度，该制度有以下两种功能，：首先，它可以监测胰腺癌的高危病患，以达到早期诊断的目的。其次，它可以作为一个生物样本的仓库，在此，病人和其家属可能提供血液，胰腺导管液和组织样本。然后医生便可以使用这些样本进行胰腺癌的相关研究，据Brett C. Sheppard医学博士说，他是俄勒冈健康科学大学（OHSU）消化健康中心的教授和副主席。
For this study, OHSU researchers in the Oregon Stem Cell Center and in the Department of General Surgery generated and characterized antibodies. These antibodies were developed following the injection of normal pancreas cells into mice. They next took the spleen cells of the mice and fused them with a myeloma cell line, which yields cells that can be grown for long periods of time in the laboratory. These cells secreted antibodies which researchers were then able to screen for reaction with normal pancreatic and pancreatic cancer tissues.
在该研究中，OHSU的研究者们在俄勒冈干细胞中心和普外学系生产并探究这些抗体。先向小鼠体内注射正常的胰腺细胞，然后便可以得到抗体。接下来，他们将小鼠的脾脏细胞与一种骨髓瘤细胞系融合，这样就可以产生能在实验室条件下长期存活的细胞。研究者们利用这些细胞所分泌的抗体去筛检正常胰腺组织和胰腺癌组织。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-12 06:42
医学,生命科学网